利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

64 条记录 (耗时 0.04 秒)

    Thyroid receptor ligands and method II
    3.
    发明授权
    Thyroid receptor ligands and method II 失效
    甲状腺受体配体及方法二

    公开(公告)号：US06989402B1

    公开(公告)日：2006-01-24

    申请号：US09868889

    申请日：1999-12-23

    申请人： Jon Hangeland ,  Minsheng Zhang ,  Yolanda Caringal ,  Denis Ryono ,  Yi-Lin Li ,  Johan Malm ,  Ye Liu ,  Neeraj Garg ,  Chris Litten ,  Ana Maria Garcia Collazo ,  Konrad Koehler

    发明人： Jon Hangeland ,  Minsheng Zhang ,  Yolanda Caringal ,  Denis Ryono ,  Yi-Lin Li ,  Johan Malm ,  Ye Liu ,  Neeraj Garg ,  Chris Litten ,  Ana Maria Garcia Collazo ,  Konrad Koehler

    IPC分类号： A61K31/44 ,  A61K31/192 ,  A61K31/40 ,  A61K31/4174 ,  C07D211/56 ,  C07D213/72 ,  C07D229/38 ,  C07D265/30 ,  C07D241/04 ,  C07D207/14

    CPC分类号： C07D207/27 ,  C07C235/32 ,  C07C235/52 ,  C07C307/06 ,  C07C311/51 ,  C07C323/41 ,  C07C323/60 ,  C07D207/09 ,  C07D211/24 ,  C07D211/34 ,  C07D211/58 ,  C07D211/96 ,  C07D213/40 ,  C07D223/12 ,  C07D231/38 ,  C07D233/64 ,  C07D257/04 ,  C07D285/06 ,  C07D285/135 ,  C07D295/13 ,  C07D295/185 ,  C07D333/20

    摘要： New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R2 and R3 being other than hydrogen; R4 is a carboxylic acid amide (CONR′R″) or an acylsulphonamide (CONHSO2R′) derivative, or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof; or when n is equal to or greater than one, R4 may be a heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR′R″). R5 is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R5=H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T3 regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.

    摘要翻译： 提供了具有通式（I）的新甲状腺受体配体，其中：n为0至4的整数; R 1是卤素，三氟甲基或1至6个碳的烷基或3至7个碳的环烷基; R 2和R 3相同或不同，为氢，卤素，1至4个碳的烷基或3至5个碳的环烷基，R 1， SUB 2和R 3不是氢; R 4是羧酸酰胺（CONR'R“）或酰基磺酰胺（CONHSO 2 R'）衍生物或其药学上可接受的盐及其所有立体异构体; 或当n等于或大于1时，R 4可以是可被取代或未取代的杂芳族部分，或胺（NR'R“）。 R 5是氢或酰基（例如乙酰基或苯甲酰基）或能够生物转化以产生游离酚结构（其中R 5 = H）的其它基团。 此外，提供了一种用于预防，抑制或治疗与代谢功能障碍相关的疾病或依赖于T 3 N调节基因的表达的方法，其中如上所述的化合物以 治疗有效量。 与代谢功能障碍相关或依赖于T 3受体基因表达的这种疾病的实例包括肥胖症，高胆固醇血症，动脉粥样硬化，心律失常，抑郁症，骨质疏松症，甲状腺机能减退，甲状腺肿，甲状腺癌以及 青光眼，充血性心力衰竭和皮肤疾病。

    Thyroid receptor ligands and method II
    4.
    发明授权
    Thyroid receptor ligands and method II 失效
    甲状腺受体配体及方法二

    公开(公告)号：US07288571B2

    公开(公告)日：2007-10-30

    申请号：US11189654

    申请日：2005-07-26

    申请人： Jon Hangeland ,  Minsheng Zhang ,  Yolanda Caringal ,  Denis Ryono ,  Yi-Lin Li ,  Johan Malm ,  Ye Liu ,  Neeraj Garg ,  Chris Litten ,  Ana Maria Garcia Collazo ,  Konrad Koehler

    发明人： Jon Hangeland ,  Minsheng Zhang ,  Yolanda Caringal ,  Denis Ryono ,  Yi-Lin Li ,  Johan Malm ,  Ye Liu ,  Neeraj Garg ,  Chris Litten ,  Ana Maria Garcia Collazo ,  Konrad Koehler

    IPC分类号： A61K31/18 ,  C07C311/50

    CPC分类号： C07D207/27 ,  C07C235/32 ,  C07C235/52 ,  C07C307/06 ,  C07C311/51 ,  C07C323/41 ,  C07C323/60 ,  C07D207/09 ,  C07D211/24 ,  C07D211/34 ,  C07D211/58 ,  C07D211/96 ,  C07D213/40 ,  C07D223/12 ,  C07D231/38 ,  C07D233/64 ,  C07D257/04 ,  C07D285/06 ,  C07D285/135 ,  C07D295/13 ,  C07D295/185 ,  C07D333/20

    摘要： New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, at least one of R2 and R3 being other than hydrogen; R4 is a carboxylic acid amide (CONR′R″) or an acylsulphonamide (CONHSO2R′) derivative, or a pharmaceutically acceptable salt thereof, and all stereolsom thereof; or when n is equal to or greater than one, R4 may be heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR′R″). R5 is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R5—H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependant upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T3 regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.

    摘要翻译： 提供了具有通式（I）的新甲状腺受体配体，其中：n为0至4的整数; R 1是卤素，三氟甲基或1至6个碳的烷基或3至7个碳的环烷基; R 2和R 3相同或不同，为氢，卤素，1至4个碳的烷基或3至5个碳的环烷基，R 1， SUB 2和R 3不是氢; R 4是羧酸酰胺（CONR'R“）或酰基磺酰胺（CONHSO 2 R'）衍生物或其药学上可接受的盐及其所有立体异构体; 或当n等于或大于1时，R 4可以是可被取代或未取代的杂芳族部分，或胺（NR'R“）。 R 5是氢或酰基（如乙酰基或苯甲酰基）或能够生物转化以产生游离酚结构的其它基团（其中R 5 -H）。 此外，提供了一种用于预防，抑制或治疗与代谢功能障碍相关的疾病或依赖于T 3 N调节基因的表达的方法，其中如上所述的化合物以 治疗有效量。 与代谢功能障碍相关或依赖于T 3受体基因表达的这种疾病的实例包括肥胖症，高胆固醇血症，动脉粥样硬化，心律失常，抑郁症，骨质疏松症，甲状腺机能减退，甲状腺肿，甲状腺癌以及 青光眼，充血性心力衰竭和皮肤疾病。

    DATA DRIVEN COMPONENT REPUTATION
    6.
    发明申请
    DATA DRIVEN COMPONENT REPUTATION 有权
    数据驱动组件信号

    公开(公告)号：US20090281819A1

    公开(公告)日：2009-11-12

    申请号：US12118760

    申请日：2008-05-12

    申请人： Neeraj Garg

    发明人： Neeraj Garg

    IPC分类号： G06Q99/00 ,  G06N5/02 ,  G06F17/30

    CPC分类号： G06N5/04 ,  G06Q50/182

    摘要： Various technologies and techniques are disclosed for observing the real-world performance of components and using the collected data to improve other user experiences. Configuration data, usage data, and user experience data are collected for components on observed solution instances. The configuration data, usage data, and user experience data are analyzed to generate component diagnostic data that can be used to make recommendations to one or more advised solution instances as to how to correct a problem being experienced on the one or more advised solution instances. In one implementation, the component diagnostic data generated includes a reputation rating for each of the components.

    摘要翻译： 公开了各种技术和技术，用于观察组件的真实性能并使用收集的数据来改善其他用户体验。 针对观察到的解决方案实例的组件收集配置数据，使用情况数据和用户体验数据。 分析配置数据，使用数据和用户体验数据以生成组件诊断数据，其可用于向一个或多个建议的解决方案实例提出关于如何纠正在一个或多个建议的解决方案实例上遇到的问题的建议。 在一个实现中，生成的组件诊断数据包括每个组件的信誉评级。

    Enabling Wake on LAN Behind NATs and Firewalls
    7.
    发明申请
    Enabling Wake on LAN Behind NATs and Firewalls 审中-公开
    启用NAT和防火墙后面的唤醒

    公开(公告)号：US20090205038A1

    公开(公告)日：2009-08-13

    申请号：US12028475

    申请日：2008-02-08

    申请人： Hemant Kumar ,  Philippe Joubert ,  Neeraj Garg

    发明人： Hemant Kumar ,  Philippe Joubert ,  Neeraj Garg

    IPC分类号： G06F17/00

    CPC分类号： H04L29/12 ,  H04L29/12339 ,  H04L29/12471 ,  H04L61/2503 ,  H04L61/2553

    摘要： Exemplary methods, computer-readable media, and systems for maintaining an inbound network path to a host in a sleep or a hibernation mode behind a plurality of network address translators (NAT) or firewalls. A network interface card (NIC) of a host is configured to periodically send or receive keep-alive packets. These packets enable network mappings that would ordinarily expire while a host is in a sleep or a hibernation mode. Power is maintained on the NIC while the host is in such mode, and the NIC responds as programmed including waking a host upon a certain event, such as receiving a data packet matching a preconfigured signature. During such time, the host may be in a wake on LAN mode.

    摘要翻译： 用于在多个网络地址转换器（NAT）或防火墙之后的睡眠或休眠模式中维护到主机的入站网络路径的示例性方法，计算机可读介质和系统。 主机的网络接口卡（NIC）被配置为周期性地发送或接收保持活动分组。 这些数据包使得当主机处于睡眠或休眠模式时通常会过期的网络映射。 当主机处于这种模式时，NIC被保持在NIC上，并且NIC响应于编程，包括在特定事件上唤醒主机，例如接收与预先配置的签名相匹配的数据包。 在此期间，主机可能处于LAN模式唤醒状态。